This is a textbook cluster-buy signal: multiple directors and 10% owners deploying ~12% of market cap in open-market purchases, with C-suite confirmation. The simultaneous derivative conversions suggest a financing or restructuring event may be imminent. Key catalyst to watch: any 8-K filing regarding a material agreement, offering, or earnings release — the cross-filing actuarial verdicts show these combos are amplifiers.
Price Chart
Executive Summary
A massive insider buying cluster at Scribe Therapeutics: six insiders (including directors OrbiMed, Carl Gordon, and Behzad Aghazadeh, plus 10% owner AH Bio Fund II) purchased a combined ~$36.2M in open-market shares over a 7-day window, with the bulk at $15/share. This represents ~12.4% of the company's $292M market cap — an extraordinarily high proportional signal. The cluster is amplified by the simultaneous conversion of derivative securities (non-cash) by the same insiders, suggesting a coordinated re-investment ahead of a potential catalyst.
Key Financial Metrics
Key Facts
- Total open-market purchases: ~$36.18M across 6 insiders in 7 days
- Largest buyers: OrbiMed Advisors ($15M), Carl Gordon ($15M), Behzad Aghazadeh ($36.1M combined across two trades)
- Purchases represent ~12.4% of SCTX's $292M market cap — far above the 2% materiality threshold
- Simultaneous conversion of derivative securities (non-cash) by multiple insiders on 2026-07-27
- AH Bio Fund II (10% owner) converted 19M+ shares from derivatives and bought $5M open-market
- C-suite participation: CFO David Parrot ($20K) and CBO Svetlana Lucas ($45K) — smaller but confirmatory
- Stock price: $15.00 for the bulk of purchases (vs. recent insider activity at $18.25)
Financial Impact
$36.18M in open-market insider purchases, representing ~12.4% of market cap — the strongest insider buy signal possible per academic literature
Risk Factors
- Insider purchases at $15 may reflect a negotiated floor price in a concurrent financing — not purely voluntary conviction
- Derivative conversions create dilution overhang (19M+ shares from AH Bio alone) that could cap upside
- Biotech sector risk: pre-revenue clinical-stage companies have binary outcomes regardless of insider signals
- Stock is thinly traded — large insider blocks may take weeks to absorb without price impact
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-SCTX-1785382142969 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 7w ago | 8-K | $30.81 $16.79 | ▼ −45.50% | ▼ −44.32% | $15.83 (−48.62%) |
Sep 2, 2026 7w ago | Press Release | $30.81 $16.79 | ▼ −45.50% | ▼ −44.32% | $15.83 (−48.62%) |
Jul 29, 2026 12w ago | Insider Cluster | $20.40 $28.84 | ▲ +41.37% | ▲ +37.41% | $15.83 (−22.40%) |
Jul 29, 2026 12w ago | Insider Cluster | $20.40 $28.84 | ▲ +41.37% | ▲ +37.41% | $15.83 (−22.40%) |
Jul 28, 2026 12w ago | Insider Cluster | $18.36 $31.70 | ▲ +72.66% | ▲ +67.64% | $15.83 (−13.78%) |
Jul 24, 2026 13w ago | 424B4 | $18.97 $37.25 | ▲ +96.36% | ▲ +93.06% | $15.83 (−16.55%) |
Jul 24, 2026 13w ago | EFFECT | $21.65 $34.13 | ▲ +57.64% | ▲ +54.02% | $15.83 (−26.88%) |
Jul 23, 2026 13w ago | 3 / PRESS-RELEASE | $21.65 $34.13 | ▲ +57.64% | ▲ +54.02% | $15.83 (−26.88%) |
Jul 20, 2026 14w ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers